Genetic Variation in Lipid Metabolism and Multiple Sclerosis Progression: Evidence for a Gene–Environment Interaction
Multiple sclerosis (MS) is a complex neurological disorder characterised by inflammation, demyelination and neurodegeneration within the central nervous system. Although substantial progress has been made in identifying genetic and environmental factors that influence the risk of developing MS, considerably less is known about the biological determinants that govern the rate at which disability accumulates after disease onset. The study by Zhang and colleagues addresses this problem by investigating whether common genetic variants associated with blood lipid concentrations or body mass index (BMI) modify disability progression in people with MS. Previous observational research had already suggested that higher total cholesterol, low-density lipoprotein (LDL), triglycerides and the total cholesterol-to-high-density lipoprotein ratio (TC:HDL), as well as lower HDL concentrations, may be associated with greater neurological disability. The central question of this study was therefore not simply whether lipid levels are associated with MS progression, but whether inherited genetic differences affecting lipid biology can alter the strength of this relationship. This distinction is scientifically important because it introduces the possibility of a gene–environment interaction, in which the clinical consequences of an environmental or metabolic exposure depend partly on an individual's genetic background.
A Longitudinal Approach to Studying MS Progression
The investigators used data from the Ausimmune Longitudinal, or AusLong, Study, a prospective cohort designed to investigate factors influencing the onset and early progression of MS. Of the original participants, 184 individuals who had developed definite MS, had Expanded Disability Status Scale (EDSS) measurements available and had undergone genome-wide genotyping were included in the analysis. The cohort was predominantly female, with women representing 81% of participants, and the mean age was approximately 38 years. At the five-year assessment, the mean EDSS score was 2.09, while the mean annualised increase in EDSS was 0.29 points. Disability progression was quantified as the annualised change in EDSS over approximately five years, providing a longitudinal measure of clinical deterioration rather than a single cross-sectional assessment. This design is a notable strength because longitudinal follow-up is particularly important in MS, where disability may fluctuate over short intervals and meaningful progression can take several years to emerge.
Linking Genetic Variants to Lipid Biology
To identify relevant genetic markers, the researchers systematically reviewed previously published genome-wide association studies examining lipid traits and BMI. Their search produced 162 lipid-associated single-nucleotide polymorphisms, or SNPs, and 97 BMI-associated SNPs for evaluation. The lipid variants had previously been associated with traits including HDL, LDL, total cholesterol and triglycerides. Genetic data were obtained using an Illumina exome genotyping platform containing approximately 244,000 exome variants together with additional MS-relevant variants. Five lipid-associated SNPs—rs2013208, rs9488822, rs17173637, rs10401969 and rs2277862—showed nominal associations with annualised disability progression. These variants were located near or within genes including RBM5, FRK, TMEM176A, CILP2 and ERGIC3. Importantly, none of the individual SNP associations remained statistically significant after stringent correction for multiple comparisons. The investigators therefore combined the five variants into a cumulative genetic risk score, reasoning that multiple small genetic effects may collectively provide a stronger indication of biological susceptibility than any single polymorphism considered independently.
A Strong Cumulative Genetic Signal
The cumulative genetic risk score produced one of the study's most notable findings. Disability progression increased in a dose-dependent manner as the number of lipid-related risk alleles increased, with a highly significant trend across genetic risk categories. Participants carrying three or fewer risk alleles had an average annualised EDSS change of approximately 0.21 points, whereas participants carrying six or more risk alleles experienced disability progression that was 0.38 EDSS points per year greater than that of the lowest-risk group. After adjustment for factors including age, sex, study site and relapse status at the five-year assessment, the cumulative genetic score explained approximately 16% of the variation in annualised disability progression. This is a substantial proportion for a complex neurological phenotype influenced by numerous genetic, biological, behavioural and treatment-related factors. Nevertheless, the result requires cautious interpretation. Two of the five SNPs demonstrated directions of effect that were not fully consistent with what would be expected from their previously established influences on lipid concentrations. The authors therefore performed a sensitivity analysis using only three biologically consistent variants; this reduced genetic score nevertheless remained strongly associated with disability progression and explained approximately 9% of the observed variation.
Evidence for Interaction Between Genes and Serum Lipids
The most scientifically significant aspect of the study may be the interaction identified between genetic susceptibility and circulating lipid levels. The cumulative lipid genetic risk score significantly modified the relationships between disability progression and both HDL concentration and the TC:HDL ratio. The interaction was statistically significant for HDL and for TC:HDL, with interaction p values of 0.005 and 0.030, respectively. As illustrated in Figure 1 on page 4 of the article, lipid levels had relatively little relationship with EDSS progression among individuals carrying four or fewer risk alleles. In contrast, among individuals with more than four risk alleles, lower HDL levels and higher TC:HDL ratios were associated with substantially greater annual disability progression. The statistical models further emphasised this interaction: HDL alone explained approximately 4% of the variation in disability progression, whereas a model incorporating HDL together with the genetic risk score explained approximately 26%. Similarly, the TC:HDL ratio alone explained around 1% of the variance, while the combined genetic and lipid model explained approximately 27%. These findings suggest that an adverse lipid profile may not exert an equivalent effect in every patient; instead, its clinical importance may depend on genetically determined biological susceptibility.
Biological Interpretation, Strengths and Important Limitations
The findings are consistent with the broader hypothesis that lipid metabolism may contribute to mechanisms underlying neuroinflammation, vascular dysfunction or neurodegeneration in MS, although the study does not establish the precise biological pathway involved. Several of the implicated loci have potentially relevant biological connections. For example, rs2013208 lies within RBM5, a gene linked to regulatory RNA biology, while rs17173637 is located within TMEM176A, which has been reported to show altered expression in people with MS. The study has several methodological strengths, including prospective follow-up, measurement of metabolic factors before much of the disability accumulation occurred, repeated clinical assessment and the use of genetically inherited markers that are unlikely to be altered by subsequent disease progression. However, the authors appropriately emphasise the principal limitation: the cohort contained only 184 participants. Such a sample is relatively small for genetic association research, particularly when examining more than one hundred genetic variants simultaneously. None of the individual lipid SNPs survived stringent correction for multiple testing, meaning that false-positive associations remain possible. The researchers attempted to address this uncertainty using permutation testing, allele-dose analyses, sensitivity analyses and cumulative genetic scoring, but they nevertheless conclude that replication in independent cohorts is essential.
Clinical Significance and Future Directions
The study provides an important conceptual framework for understanding why metabolic risk factors may have different consequences among people living with MS. Rather than viewing serum cholesterol solely as a universal predictor of progression, the results suggest that the influence of lipid metabolism may be partly conditional on an individual's genetic background. This possibility could eventually contribute to more personalised approaches to prognosis and treatment. The authors specifically raise the possibility that inconsistent results from previous clinical trials of statins in MS might partly reflect genetic heterogeneity: lipid-lowering therapy could theoretically offer greater benefit to individuals whose genetic profile makes them particularly susceptible to the neurological consequences of dyslipidaemia. Such an interpretation remains hypothetical and should not yet be used to guide clinical treatment, because the reported genetic associations require validation and functional investigation. Nevertheless, the study demonstrates that combining genetic markers with measurable metabolic factors may explain considerably more variation in MS disability progression than either category alone. The authors ultimately conclude that lipid-related genetic variants and serum lipid profiles appear to act jointly in influencing early disability accumulation, with combined models accounting for more than one quarter of disability variation in this cohort. Future research involving larger and more diverse populations, functional studies of the implicated genes, and prospective intervention trials stratified by genetic risk will be necessary to determine whether this gene–lipid interaction can be transformed from an epidemiological observation into a clinically useful biomarker or therapeutic strategy.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Zhang, Y., Zhou, Y., Van Der Mei, I. A., Simpson, S., Ponsonby, A. L., Lucas, R. M., ... & Ausimmune/AusLong Investigators Group. (2019). Lipid-related genetic polymorphisms significantly modulate the association between lipids and disability progression in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry, 90(6), 636-641.
